Key result
Sirt1 activation with resveratrol or overexpression protected against cardiac hypertrophy, metabolic dysregulation, and inflammation in vitro and in vivo through a PPARα-dependent mechanism.
Why the study?
Does Sirt1 activation with resveratrol or overexpression prevent cardiac hypertrophy, metabolic dysregulation, and inflammation in neonatal cardiomyocytes and mice?
Population
Neonatal cardiomyocytes (NCMs) in vitro and wild-type vs PPARα-null mice in vivo
Comparison
Sirt1 activation with resveratrol or Sirt1… vs Control conditions
Design
Preclinical
Authors
Loading...
Hypothesis-generating for Sirt1-PPARα targeting in hypertrophy models; leaves open clinical translation.
Does Sirt1 activation with resveratrol or overexpression prevent cardiac hypertrophy, metabolic dysregulation, and inflammation in neonatal cardiomyocytes and mice?
Sirt1 protects against cardiac hypertrophy, metabolic dysregulation, and inflammation through a PPARα-dependent mechanism.
Planavila et al. (2010) studied Cardiac hypertrophy. Sirt1 activation (resveratrol) or overexpression vs. Control / PPARα inhibition / PPARα-null mice was evaluated on Cardiac hypertrophy, metabolic dysregulation, and inflammation. Sirt1 activation with resveratrol or overexpression protected against cardiac hypertrophy, metabolic dysregulation, and inflammation in vitro and in vivo through a PPARα-dependent mechanism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: